Literature DB >> 29206910

State Medicaid Hepatitis C Treatment Eligibility Criteria and Use of Direct-Acting Antivirals.

Shashi N Kapadia1, Philip J Jeng2, Bruce R Schackman2, Yuhua Bao2.   

Abstract

Medicaid program criteria for accessing hepatitis C treatment are changing. Medicaid drug utilization data from 2014 to 2016 show that programs that have relaxed their criteria have seen significant increases in treatment utilization, as have states with Medicaid expansions.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29206910      PMCID： PMC6248367          DOI： 10.1093/cid/cix1062

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  4 in total

1.  Toward a more accurate estimate of the prevalence of hepatitis C in the United States.

Authors:  Brian R Edlin; Benjamin J Eckhardt; Marla A Shu; Scott D Holmberg; Tracy Swan
Journal:  Hepatology       Date:  2015-08-25       Impact factor: 17.425

2.  Restrictions of Hepatitis C Treatment for Substance-Using Medicaid Patients: Cost Versus Ethics.

Authors:  Joshua M Liao; Michael A Fischer
Journal:  Am J Public Health       Date:  2017-04-20       Impact factor: 9.308

3.  Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013.

Authors:  Kathleen N Ly; Elizabeth M Hughes; Ruth B Jiles; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2016-03-01       Impact factor: 9.079

4.  Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010.

Authors:  Maxine M Denniston; Ruth B Jiles; Jan Drobeniuc; R Monina Klevens; John W Ward; Geraldine M McQuillan; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391
  4 in total
  8 in total

1.  Drug Costs: What Can Infectious Diseases Physicians Do?

Authors:  Shashi N Kapadia; Roy M Gulick
Journal:  J Infect Dis       Date:  2020-02-18       Impact factor: 5.226

2.  Hepatitis C Virus Infection in the Dallas County Jail: Implications for Screening, Prevention, and Linkage to Care.

Authors:  Caroline M Abe; Merilyne Aguwa; Michelle Zhao; Jacqueline Sullivan; Esmaeil Porsa; Ank E Nijhawan
Journal:  Public Health Rep       Date:  2019-09-17       Impact factor: 2.792

3.  The Effects of Hepatitis C Treatment Eligibility Criteria on All-cause Mortality Among People With Human Immunodeficiency Virus.

Authors:  Alexander Breskin; Daniel Westreich; Christopher B Hurt; Stephen R Cole; Michael G Hudgens; Eric C Seaberg; Chloe L Thio; Phyllis C Tien; Adaora A Adimora
Journal:  Clin Infect Dis       Date:  2019-10-15       Impact factor: 20.999

4.  Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs.

Authors:  Sarah Gutkind; Laura E Starbird; Sean M Murphy; Paul A Teixeira; Lauren K Gooden; Tim Matheson; Daniel J Feaster; Mamta K Jain; Carmen L Masson; David C Perlman; Carlos Del Rio; Lisa R Metsch; Bruce R Schackman
Journal:  Drug Alcohol Depend       Date:  2022-01-10       Impact factor: 4.852

5.  Prevalence of Hepatitis C Virus Infection Identified From Nontargeted Screening Among Adult Visitors in an Academic Appalachian Regional Emergency Department.

Authors:  J Daniel Moore; James Galbraith; Roger Humphries; Jennifer R Havens
Journal:  Open Forum Infect Dis       Date:  2021-08-04       Impact factor: 3.835

6.  Rapid Treatment Initiation for Hepatitis C in Young People Who Inject Drugs: The Seek, Test, and Rapid Treatment Randomized Trial.

Authors:  Benjamin Eckhardt; Shashi N Kapadia; Pedro Mateu-Gelabert; Melinda Pai; Chunki Fong; Yesenia Aponte-Melendez; Kristen M Marks
Journal:  Open Forum Infect Dis       Date:  2022-05-07       Impact factor: 4.423

7.  The Impact of Supportive Housing on Liver-Related Outcomes Among Persons With Hepatitis C Virus Infection.

Authors:  Sara A Miller-Archie; Sarah C Walters; Angelica Bocour; Miranda S Moore; Ellen Wiewel; Tejinder Singh; Sungwoo Lim
Journal:  J Infect Dis       Date:  2022-10-07       Impact factor: 7.759

8.  Pathways to ensure universal and affordable access to hepatitis C treatment.

Authors:  Caitlin H Douglass; Alisa Pedrana; Jeffrey V Lazarus; Ellen F M 't Hoen; Radi Hammad; Ricardo Baptista Leite; Andrew Hill; Margaret Hellard
Journal:  BMC Med       Date:  2018-10-09       Impact factor: 8.775
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.